Current methods for detecting antibodies against erythropoietin and other recombinant proteins

Clinical and Diagnostic Laboratory Immunology

Volumn 12, Issue 1, 2005, Pages 28-39

  Thorpe, Robin ^a   Swanson, Steven J ^b  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPOPEN; ERYTHROPOIETIN; NEUTRALIZING ANTIBODY; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; RECOPEN;

ANEMIA; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIGEN BINDING; BIOSENSOR; CHRONIC KIDNEY DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE APLASIA; HUMAN; IMMUNOASSAY; PRIORITY JOURNAL; RADIOIMMUNOPRECIPITATION; SENSITIVITY AND SPECIFICITY; SHORT SURVEY;

ANEMIA; ANTI-BACTERIAL AGENTS; ERYTHROPOIETIN; HUMANS; IMMUNOASSAY; KIDNEY DISEASES; RECOMBINANT PROTEINS; RED-CELL APLASIA, PURE; SENSITIVITY AND SPECIFICITY;

EID: 12744273875     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/CDLI.12.1.28-39.2005     Document Type: Short Survey

References (99)

1. Amgen, Inc. Amgen statement on pure red cell aplasia. [Online.] www.amgen.com/clinicians/prca.html.
2. Arranz, O., J. Ara, R. Rodriguez, L. Quinto, J. Font, E. Mirapeix, and A. Darnell. 2001. Comparison of anti-PR3 capture and anti-PR3 direct ELISA for detection of antineutrophil cytoplasmic antibodies (ANCA) in long-term clinical follow-up of PR3-ANCA-associated vasculitis patients. Clin. Nephrol. 56:295-301.
3. Baron, E. J., D. E. Weber, and L. G. Weide. 1996. Lack of agreement among two commercial enzyme-linked immunosorbent antibody assays and a conventional immunofluorescence-based method for detecting islet cell autoantibodies. Clin. Diagn. Lab. Immunol. 3:429-431.
4. Basser, R. L., E. O'Flaherty, M. Green, M. Edmonds, J. Nichol, D. M. Menchaca, B. Cohen, and C. G. Begley. 2002. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 99:2599-2602.
5. Bendtzen, K., M. B. Hansen, C. Ross, and M. Svenson. 2000. Detection of autoantibodies to cytokines. Mol. Biotechnol. 14:251-261.
6. Bergrem, H., B. G. Danielson, K. U. Eckardt, A. Kurtz, and M. Stridsberg. 1993. A case of antierythropoietin antibodies following recombinant human erythropoietin treatment, p. 265-275. In P. Sciqalla (ed.), Erythropoietin: molecular physiology and clinical application. Marcel Dekker, New York, N.Y.
7. Black, J. B., T. F. Schwarz, J. L. Patton, K. Kite-Powell, P. E. Pellett, S. Wiersbitzky, R. Bruns, C. Muller, G. Jager, and J. A. Stewart. 1996. Evaluation of immunoassays for detection of antibodies to human herpesvirus 7. Clin. Diagn. Lab. Immunol. 3:79-83.
8. Boissel, J. P., W. R. Lee, S. R. Presnell, F. E. Cohen, and H. F. Bunn. 1993. Erythropoietin structure-function relationships. Mutant proteins that test a model of tertiary structure. J. Biol. Chem. 268:15983-15993.
9. Bommer, J., and J. Wagner. 2003. Safety of Aranesp (darbepoetin alfa) in dialysis patients with renal anaemia-results of a German mulitcentre study in 1502 patients. Nephrol. Dial. Transplant. 18(Suppl. 4):165.
10. Bonfield, T. L., M. S. Kavuru, and M. J. Thomassen. 2002. Anti-GM-CSF titer predicts response to GM-CSF therapy in pulmonary alveolar proteinosis. Clin. Immunol. 105:342-350.
11. Buchalter, M. B., G. Suntharalingam, I. Jennings, C. Hart, R. J. Luddington, R. Chakraverty, S. K. Jacobson, P. L. Weissberg, and T. P. Baglin. 1992. Streptokinase resistance: when might streptokinase administration be ineffective? Br. Heart J. 68:449-453.
12. Casadevall, N. 2002. Antibodies against rHuEPO: native and recombinant. Nephrol. Dial. Transplant. 17(Suppl. 5):42-47.
13. Casadevall, N., E. Dupuy, P. Molho-Sabatier, G. Tobelem, B. Varet, and P. Mayeux. 1996. Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N. Engl. J. Med. 334:630-633.
14. Casadevall, N., J. Nataf, B. Viron, A. Kolta, J. J. Kiladjian, P. Martin-Dupont, P. Michaud, T. Papo, V. Ugo, I. Teyssandier, B. Varet, and P. Mayeux. 2002. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346: 469-475.
15. Cassano, W. F. 1989. Murine monoclonal anti-avidin antibodies enhance the sensitivity of avidin-biotin immunoassays and immunohistologic staining. J. Immunol. Methods 117:169-174.
16. Castelli, G., A. Famularo, C. Semino, A. M. Machi, A. Ceci, G. Cannella, and G. Melioli. 2000. Detection of anti-erythropoietin antibodies in haemodialysis patients treated with recombinant human-erythropoietin. Pharmacol. Res. 41:313-318.
17. Chretien, S., P. Varlet, F. Verdier, S. Gobert, J. P. Cartron, S. Gisselbrecht, P. Mayeux, and C. Lacombe. 1996. Erythropoietin-induced erythroid differentiation of the human erythroleukemia cell line TF-1 correlates with impaired STAT5 activation. EMBO J. 15:4174-4181.
18. Conlon, K. C., W. J. Urba, J. W. Smith II, R. G. Steis, D. L. Longo, and J. W. Clark. 1990. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer 65:2237-2242.
19. Cotes, P. M., and D. R. Bangham. 1966. The international reference preparation of erythropoietin. Bull. W. H. O. 35:751-760.
20. Crombet, T., O. Torres, V. Rodriguez, A. Menendez, A. Stevenson, M. Ramos, F. Torres, R. Figueredo, I. Veitia, N. Iznaga, R. Perez, and A. Lage. 2001. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study. Hybridoma 20:131-136.
21. Crooks, S. R., G. A. Baxter, M. C. O'Connor, and C. T. Elliot. 1998. Immunobiosensor - an alternative to enzyme immunoassay screening for residues of two sulfonamides in pigs. Analyst 123:2755-2757.
22. Dai, Y., E. M. Schwarz, D. Gu, W. W. Zhang, N. Sarvetnick, and I. M. Verma. 1995. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc. Natl. Acad. Sci. USA 92:1401-1405.
23. Dayan, P., F. Ahmad, J. Urtecho, M. Novick, P. Dixon, D. Levine, and S. Miller. 2002. Test characteristics of the respiratory syncytial virus enzyme-linked immunoabsorbent assay in febrile infants < or = 60 days of age. Clin. Pediatr. (Philadelphia) 41:415-418.
24. Egrie, J. C., P. M. Cotes, J. Lane, R. E. Gaines Das, and R. C. Tam. 1987. Development of radioimmunoassays for human erythropoietin using recombinant erythropoietin as tracer and immunogen. J. Immunol. Methods 99:235-241.
25. Field, P. R., J. L. Mitchell, A. Santiago, D. J. Dickeson, S. W. Chan, D. W. Ho, A. M. Murphy, A. J. Cuzzubbo, and P. L. Devine. 2000. Comparison of a commercial enzyme-linked immunosorbent assay with immunofluorescence and complement fixation tests for detection of Coxiella burnetii (Q fever) immunoglobulin M. J. Clin. Microbiol. 38:1645-1647.
26. Garotta, G., L. Ozmen, M. Fountoulakis, Z. Dembic, A. P. van Loon, and D. Stuber. 1990. Human interferon-gamma receptor. Mapping of epitopes recognized by neutralizing antibodies using native and recombinant receptor proteins. J. Biol. Chem. 265:6908-6915.
27. Ge, Y., S. Powell, M. Van Roey, and J. G. McArthur. 2001. Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX. Blood 97:3733-3737.
28. Gershon, S. K., H. Luksenburg, T. R. Cote, and M. M. Braun. 2002. Pure red-cell aplasia and recombinant erythropoietin. N. Engl. J. Med. 346: 1584-1586.
29. Giovanella, L., and L. Ceriani. 2002. High-sensitivity human thyroglobulin (hTG) immunoradiometric assay in the follow-up of patients with differentiated thyroid cancer. Clin. Chem. Lab. Med. 40:480-484.
30. Griffiths, P. D., and H. O. Kangro. 1984. A user's guide to the indirect solid-phase radioimmunoassay for the detection of cytomegalovirus-specific IgM antibodies. J. Virol. Methods 8:271-282.
31. Grossberg, S. E., Y. Kawade, M. Kohase, H. Yokoyama, and N. Finter. 2001. The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems. J. Interferon Cytokine Res. 21:729-742.
32. Gussin, H. A., K. L. Russo, and M. Teodorescu. 2000. Effect of circulating immune complexes on the binding of rheumatoid factor to histones. Ann. Rheum. Dis. 59:351-358.
33. Hammerling, U., R. Kroon, T. Wilhelmsen, and L. Sjodin. 1996. In vitro bioassay for human erythropoietin based on proliferative stimulation of an erythroid cell line and analysis of carbohydrate-dependent microheterogeneity. J. Pharm. Biomed. Anal. 14:1455-1469.
34. Hansen, K. 1994. Lyme neuroborreliosis: improvements of the laboratory diagnosis and a survey of epidemiological and clinical features in Denmark 1985-1990. Acta Neurol. Scand. Suppl. 151:1-44.
35. Hansen, M. B., C. Ross, and K. Berg. 1990. A sensitive antiviral neutralization bioassay for measuring antibodies to interferons. J. Immunol. Methods. 127:241-248.
36. Hansen, P. J. Analysis of proteins by immunoprecipitation. [Online.] http: //www.dps.un.edu/hansen/protocols/imp98.prt.htm.
37. Harris, K. W., X. J. Hu, S. Schultz, M. O. Arcasoy, B. G. Forget, and N. Clare. 1998. The distal cytoplasmic domain of the erythropoietin receptor induces granulocytic differentiation in 32D cells. Blood 92:1219-1224.
38. Hellmich, B., E. Csernok, H. Schatz, W. L. Gross, and A. Schnabel. 2002. Autoantibodies against granulocyte colony-stimulating factor in Felty's syndrome and neutropenic systemic lupus erythematosus. Arthritis Rheum. 46: 2384-2391.
39. Hennes, U., W. Jucker, E. A. Fischer, T. Krummenacher, A. V. Palleroni, P. W. Trown, S. Linder-Ciccolunghi, and M. Rainisio. 1987. The detection of antibodies to recombinant interferon alfa-2a in human serum. J. Biol. Stand. 15:231-244.
40. Hennig, C., L. Rink, U. Fagin, W. J. Jabs, and H. Kirchner. 2000. The influence of naturally occurring heterophilic anti-immunoglobulin antibodies on direct measurement of serum proteins using sandwich ELISAs. J. Immunol. Methods 235:71-80.
41. Hjelm Skog, A. L., M. Wadhwa, M. Hassan, B. Gharizadeh, C. Bird, P. Ragnhammar, R. Thorpe, and H. Mellstedt. 2001. Alteration of interleukin 2 (IL-2) pharmacokinetics and function by IL-2 antibodies induced after treatment of colorectal carcinoma patients with a combination of monoclonal antibody 17-1A, granulocyte macrophage colony-stimulating factor, and IL-2. Clin. Cancer Res. 7:1163-1170.
42. Itri, L. M., M. Campion, R. A. Dennin, A. V. Palleroni, J. U. Gutterman, J. E. Groopman, and P. W. Trown. 1987. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alfa-2a by intramuscular injection. Cancer 59:668-674.
43. Jacobs, K., C. Shoemaker, R. Rudersdorf, S. D. Neill, R. J. Kaufman, A. Mufson, J. Seehra, S. S. Jones, R. Hewick, E. F. Fritsch, et al. 1985. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 313:806-810.
44. Jacobs-Helber, S. M., A. Wickrema, M. J. Birrer, and S. T. Sawyer. 1998. AP1 regulation of proliferation and initiation of apoprosis in erythropoietin-dependent erythroid cells. Mol. Cell. Biol. 18:3699-3707.
45. Johnson & Johnson. Summary of PRCA case reports. [Online.] http://www.jnj.com/news/jnj_news/1021024_095632.htm.
46. Koren, E., L. A. Zuckerman, and A. R. Mire-Sluis. 2002. Immune responses to therapeutic proteins in humans-clinical significance, assessment and prediction. Curr. Pharm. Biotechnol. 3:349-360.
47. Krantz, S. B., and V. Kao. 1967. Studies on red cell aplasia. I. Demonstration of a plasma inhibitor to heme synthesis and an antibody to erythroblast nuclei. Proc. Natl. Acad. Sci. USA 58:493-500.
48. Krantz, S. B., and V. Kao. 1969. Studies on red cell aplasia. II. Report of a second patient with an antibody to erythroblast nuclei and a remission after immunosuppressive therapy. Blood 34:1-13.
49. Krantz, S. B., W. H. Moore, and S. D. Zaentz. 1973. Studies on red cell aplasia. V. Presence of erythroblast cytotoxicity in G-globulin fraction of plasma. J. Clin. Investig. 52:324-336.
50. Kuroki, M., Y. Matsumoto, F. Arakawa, M. Haruno, M. Murakami, M. Kuwahara, H. Ozaki, T. Senba, and Y. Matsuoka. 1995. Reducing interference from heterophilic antibodies in a two-site immunoassay for carcinoembryonic antigen (CEA) by using a human/mouse chimeric antibody to CEA as the tracer. J. Immunol. Methods 180:81-91.
51. Lackmann, M., T. Bucci, R. J. Mann, L. A. Kravets, E. Viney, F. Smith, R. L. Moritz, W. Carter, R. J. Simpson, N. A. Nicola, K. Mackwell, E. C. Nice, A. F. Wilks, and A. W. Boyd. 1996. Purification of a ligand for the EPH-like receptor HEK using a biosensor-based affinity detection approach. Proc. Natl. Acad. Sci. USA 93:2523-2527.
52. Lacombe, C., N. Casadevall, O. Muller, and B. Varet. 1984. Erythroid progenitors in adult chronic pure red cell aplasia: relationship of in vitro erythroid colonies to therapeutic response. Blood 64:71-77.
53. Leon, A. D., M. Tellez Araiza, J. Arellano Garcia, and E. Martinez-Cordero. 2002. Interference by rheumatoid factor activity in the detection of antiavian antibodies in pigeon breeders disease. Clin. Exp. Med. 2:59-67.
54. Li, J., C. Yang, Y. Xia, A. Bertino, J. Glaspy, M. Roberts, and D. J. Kuter. 2001. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98:3241-3248.
55. Liebe, V., M. Bruckmann, K. G. Fischer, K. K. Haase, M. Borggrefe, and G. Huhle. 2002. Biological relevance of anti-recombinant hirudin antibodies - results from in vitro and in vivo studies. Semin. Thromb. Hemost. 28: 483-490.
56. Lin, F. K., S. Suggs, C. H. Lin, J. K. Browne, R. Smalling, J. C. Egrie, K. K. Chen, G. M. Fox, F. Martin, Z. Stabinsky, et al. 1985. Cloning and expression of the human erythropoietin gene. Proc. Natl. Acad. Sci. USA 82: 7580-7584.
57. Linardaki, G. D., K. A. Boki, A. Fertakis, and A. G. Tzioufas. 1999. Pure red cell aplasia as presentation of systemic lupus erythematosus: antibodies to erythropoietin. Scand. J. Rheumatol. 28:189-191.
58. Lynch, M., B. L. Pentecost, W. A. Littler, and R. A. Stockley. 1996. The distribution of antibodies to streptokinase. Postgrad. Med. J. 72:290-292.
59. Meager, A., M. Wadhwa, P. Dilger, C. Bird, R. Thorpe, J. Newsom-Davis, and N. Willcox. 2003. Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin. Exp. Immunol. 132:128-136.
60. Millett, B., A. M. Sullivan, M. Morimoto, and G. Parsons. 1994. A third generation immunoassay for tumor necrosis factor alpha. BioTechniques 17:1166-1171.
61. Mimms, L., A. Goetze, S. Swanson, M. Floreani, B. Edwards, J. Macioszek, G. Okasinski, and W. Kiang. 1989. Second generation assays for the detection of antibody to HBsAg using recombinant DNA-derived HBsAg. J. Virol. Methods 25:211-231.
62. Mobini, R., M. Fu, G. Wallukat, Y. Magnusson, A. Hjalmarson, and J. Hoebeke. 2000. A monoclonal antibody directed against an autoimmune epitope on the human beta1-adrenergic receptor recognized in idiopathic dilated cardiomyopathy. Hybridoma 19:135-142.
63. Mobini, R., A. Staudt, S. B. Felix, G. Baumann, G. Wallukat, J. Deinum, H. Svensson, A. Hjalmarson, and M. Fu. 2003. Hemodynamic improvement and removal of autoantibodies against beta(1)-adrenergic receptor by immunoadsorption therapy in dilated cardiomyopathy. J. Autoimmun. 20: 345-350.
64. Moffatt, S., N. Yaegashi, K. Tada, N. Tanaka, and K. Sugamura. 1998. Human parvovirus B19 nonstructural (NS1) protein induces apoprosis in erythroid lineage cells. J. Virol. 72:3018-3028.
65. Moore, M. Developmental hematopoiesis. [Online.] http://www.mskcc.org/ mskcc/html/10645.cfm.
66. Nice, E., J. Layton, L. Fabri, U. Hellman, A. Engstrom, B. Persson, and A. W. Burgess. 1993. Mapping of the antibody- and receptor-binding domains of granulocyte colony-stimulating factor using an optical biosensor. Comparison with enzyme-linked immunosorbent assay competition studies. J. Chromatogr. 646:159-168.
67. Peces, R., M. de la Torre, R. Alcazar, and J. M. Urra. 1996. Antibodies against recombinant human erythropoietin in a patient with erythropoietin- resistant anemia. N. Engl. J. Med. 335:523-524.
68. Peschle, C., A. M. Marmont, G. Marone, A. Genovese, G. F. Sasso, and M. Condorelli. 1975. Pure red cell aplasia: studies on an IgG serum inhibitor neutralizing erythropoietin. Br. J. Haematol. 30:411-417.
69. Prabhakar, S. S., and T. Muhlfelder. 1997. Antibodies to recombinant human erythropoietin causing pure red cell aplasia. Clin. Nephrol. 47: 331-335.
70. Rasooly, A. 2001. Surface plasmon resonance analysis of staphylococcal enterotoxin B in food. J. Food Prot. 64:37-43.
71. Ritter, G., L. S. Cohen, C. Williams, Jr., E. C. Richards, L. J. Old, and S. Welt. 2001. Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res. 61:6851-6859.
72. Rosenberg, A. S. 2003. Immunogenicity of biological therapeutics: a hierarchy of concerns. Dev. Biol. (Basel) 112:15-21.
73. Schellekens, H. 2002. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin. Ther. 24:1720-1740.
74. Suter, M., and J. E. Butler. 1986. The immunochemistry of sandwich ELISAs. II. A novel system prevents the denaturation of capture antibodies. Immunol. Lett. 13:313-316.
75. Svenson, M., M. B. Hansen, C. Ross, M. Diamant, K. Rieneck, H. Nielsen, and K. Bendtzen. 1998. Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations. Blood 91:2054-2061.
76. Svojanovsky, S. R., K. L. Egodage, J. Wu, M. Slavik, and G. S. Wilson. 1999. High sensitivity ELISA determination of taxol in various human biological fluids. J. Pharm. Biomed. Anal. 20:549-555.
77. Swanson, S. J. 2004. Detection of baseline anti-erythropoietin antibodies in patients with chronic kidney disease, using the BIA core immunoassay. Presented at the 41st Congress of the European Renal Association and European Dialysis and Transplant Association, Lisbon, Portugal, July 17, 2003.
78. Swanson, S. J. 2003. New technologies for the detection of antibodies to therapeutic proteins, p. 127-133. In A. R. Mire-Sluis (ed.), Immunogenicity of therapeutic biological products, vol. 112. Karger, Basel, Switzerland.
79. Swanson, S. J., J. Ferbas, P. Mayeux, and N. Casadevall. 2004. Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin. Nephron. Clin Pract. 96:c88-c95.
80. Swanson, S. J., S. J. Jacobs, D. Mytych, C. Shah, S. R. Indelicato, and R. W. Bordens. 1999. Applications for the new electrochemiluminescent (ECL) and biosensor technologies. Dev. Biol. Stand. 97:135-147.
81. Swedler, W., J. Wallman, C. J. Froelich, and M. Teodorescu. 1997. Routine measurement of IgM, IgG, and IgA rheumatoid factors: high sensitivity, specificity, and predictive value for rheumatoid arthritis. J. Rheumatol. 24: 1037-1044.
82. Swissmedic. 2003. Nouvel effet indésirable grave mais rare de l'érythropoïétine recombinante. Swissmedic medical update letter. [Online.] http://www .swissmedic.ch/en/laien/overall.asp?lang = 2&theme=0.00062.00004 .00001&theme_id=810&news_id=2588&page=1.
83. Sytkowski, A. J., and K. A. Donahue. 1987. Immunochemical studies of human erythropoietin using site-specific anti-peptide antibodies. Identification of a functional domain. J. Biol. Chem. 262:1161-1165.
84. Takacs, M. A., S. J. Jacobs, R. M. Bordens, and S. J. Swanson. 1999. Detection and characterization of antibodies to PEG-IFN-α2b using surface plasmon resonance. J. Interferon Cytokine Res. 19:781-789.
85. Takatoku, M., M. Kametaka, R. Shimizu, Y. Miura, and N. Komatsu. 1997. Identification of functional domains of the human thrombopoietin receptor required for growth and differentiation of megakaryocytic cells. J. Biol. Chem. 272:7259-7263.
86. Ullenhag, G., C. Bird, P. Ragnhammar, J. E. Frodin, K. Strigard, O. I. A., R. Thorpe, H. Mellstedt, and M. Wadhwa. 2001. Incidence of GM-CSF antibodies in cancer patients receiving GM-CSF for immunostimulation. Clin. Immunol. 99:65-74.
87. Urra, J. M., M. de la Torre, R. Alcazar, and R. Peces. 1997. Rapid method for detection of anti-recombinant human erythropoietin antibodies as a new form of erythropoietin resistance. Clin. Chem. 43:848-849.
88. VanCott, T. C., L. D. Loomis, R. R. Redfield, and D. L. Birx. 1992. Real-time biospecific interaction analysis of antibody reactivity to peptides from the envelope glycoprotein, gp160, of HIV-1. J. Immunol. Methods 146:163-176.
89. Van Der Geld, Y. M., P. C. Limburg, and C. G. Kallenberg. 1999. Characterization of monoclonal antibodies to proteinase 3 (PR3) as candidate tools for epitope mapping of human anti-PR3 autoantibodies. Clin. Exp. Immunol. 118:487-496.
90. Vyse, A. J., W. A. Knowles, B. J. Cohen, and D. W. Brown. 1997. Detection of IgG antibody to Epstein-Barr virus viral capsid antigen in saliva by antibody capture radioimmunoassay. J. Virol. Methods 63:93-101.
91. Wadhwa, M., C. Bird, P. Dilger, R. Gaines-Das, and R. Thorpe. 2003. Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals. J. Immunol. Methods 278: 1-17.
92. Wadhwa, M., C. Bird, J. Fagerberg, R. Gaines-Das, P. Ragnhammar, H. Mellstedt, and R. Thorpe. 1996. Production of neutralizing granulocyte- macrophage colony-stimulating factor (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy. Clin. Exp. Immunol. 104: 351-358.
93. Wadhwa, M., A. L. Skog, C. Bird, P. Ragnhammar, M. Lilljefors, R. Gaines-Das, H. Mellstedt, and R. Thorpe. 1999. Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF. Clin. Cancer Res. 5: 1353-1361.
94. Weber, G., J. Gross, A. Kromminga, H. H. Loew, and K. U. Eckardt. 2002. Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins. J. Am. Soc. Nephrol. 13:2381-2383.
95. Wong, R. L., D. Mytych, S. Jacobs, R. Bordens, and S. J. Swanson. 1997. Validation parameters for a novel biosensor assay which simultaneously measures serum concentrations of a humanized monoclonal antibody and detects induced antibodies. J. Immunol. Methods 209:1-15.
96. Wu, G., B. Nathoo, D. Mendelssohn, S. Pandeya, and P. Tam. 2003. Antibody to erythropoietin surveillance study in 5 Ontario renal centres. Nephrol. Dial. Transplant. 18(Suppl. 4):162.
97. Zang, Y. C., D. Yang, J. Hong, M. V. Tejada-Simon, V. M. Rivera, and J. Z. Zhang. 2000. Immunoregulation and blocking antibodies induced by interferon beta treatment in MS. Neurology 55:397-404.
98. Zhong, D., E. L. Saenko, M. Shima, M. Felch, and D. Scandella. 1998. Some human inhibitor antibodies interfere with factor VIII binding to factor IX. Blood 92:136-142.
99. Zhu, G., B. Yang, and R. N. Jennings. 2000. Quantitation of basic fibroblast growth factor by immunoassay using BIAcore 2000. J. Pharm. Biomed. Anal. 24:281-290.